Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout

Novartis Pharma launched Kesimpta Subcutaneous Injection (ofatumumab), a human anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS), on May 24. With Mayzent (siponimod) and Gilenya (fingolimod) in its current MS portfolio, the Japan arm of Swiss titan Novartis...read more